PSMA-PETSBRT (PROBE):

Maneesh Singh1, Aparna Katdare2, Suchismita Ghosh3

  • 1Department of Radiation Oncology, Tata Memorial Hospital and Advanced Centre for Treatment Research and Education in Cancer, Homi Bhabha National Institute, Mumbai, India.

概括

68-前列腺特异性膜抗原 (PSMA) -PET/CT与前列腺MRI相结合SBRT增强计划显示体积相似性但空间一致性较差. 这种PSMA-PET指导的增强似乎是安全的剂量升级,与低急性毒性.